Press Releases

GlobeNewswire, Inc.

PHILADELPHIA, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Kehoe Law Firm, P.C. is investigating potential securities claims on behalf of investors of MNTN, Inc. ("MNTN" or the "Company") (NYSE: MNTN) following the Company’s November 4, 2026 disclosures...

GlobeNewswire, Inc.

– Generated Record Quarterly Net Revenues of $216.3 Million, Up 3% Year-over-Year – – Generated Record JORNAY PM® Quarterly Net Revenue of $51.9 Million, Up 24% Year-over-Year – – Generated AZSTARYS® Quarterly Net Revenue of $26.5 Million in First...

GlobeNewswire, Inc.

Adult and adolescent cohorts fully enrolled in registrational SAFEGUARD study of SAB-142; Pediatric cohort (ages 5–11) actively enrolling with overall enrollment on track for completion in Q4 2026 Received FDA Fast Track designation for SAB-142 in...

GlobeNewswire, Inc.

FDA Accepts NDA for QTORIN™ Rapamycin and Grants Priority Review for Microcystic Lymphatic Malformations; PDUFA Target Action Date Set for February 28, 2027 QTORIN™ Rapamycin Could Become the First FDA-Approved Therapy for Microcystic Lymphatic...

GlobeNewswire, Inc.

RESET-Myositis® registrational adult topline results anticipated in 2H27 with BLA submission in 1Q28, including Phase 1/2 juvenile dermatomyositis data for potential PRV eligibility and Phase 1/2 adult durability data Immunomodulator-free...

GlobeNewswire, Inc.

- Biologics License Application (BLA) for z-rostudirsen in exon 51 Duchenne muscular dystrophy (DMD) under priority review by FDA; PDUFA target action date of January 21, 2027 - - Additional one-year clinical data from Phase 1/2 ACHIEVE trial of...

GlobeNewswire, Inc.

NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- Teads Holding Co. (Nasdaq: TEAD), the omnichannel outcomes platform (the “Company” or “Teads”), today announced the appointment of Michael Coyle as Chief Financial Officer, effective November 11, 2026....

GlobeNewswire, Inc.

Third Quarter Revenue of $42.7 Million, Up 12% Year-over-Year Exchange Revenue Grew 24% Year-over-Year to $25.5 Million Adjusted EBITDA of $1.1 Million vs $0.2 Million in the Prior Year (All monetary figures are expressed in Canadian dollars...

GlobeNewswire, Inc.

Revenue was $809 million, up 5.3%, and up 7.4% on an organic constant currency (OCC) basis, a non-GAAP measure.

GlobeNewswire, Inc.

RENO, Nev., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) (“Dragonfly Energy” or the “Company”), an industry leader in lithium battery technology, today announced that the Company will release its financial and...

GlobeNewswire, Inc.

Declares Regular Quarterly Dividend Board Authorizes $20M Share Repurchase Program GARDEN CITY, N.Y., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Lifetime Brands, Inc. (NasdaqGS: LCUT), a leading global designer, developer and marketer of a broad range of...

GlobeNewswire, Inc.

Third Consecutive Quarter with Year-over-Year Revenue Growth GAAP Net Cash Provided by Operating Activities was $146 million, an increase of $74 million or 103% year-over-year.

GlobeNewswire, Inc.

Quarterly net revenues of $290.8 million, an increase of 27.6% year-over-year Purified Cortrophin® Gel net revenues of $138.7 million, an increase of 36.1% year-over-year Quarterly GAAP net income available to common shareholders of $35.1 million;...

GlobeNewswire, Inc.

Third quarter milestones included a definitive power agreement that removes approximately $33 million of upfront costs from the construction budget and enactment of new Brazilian legislation, Profert, favorable to the Company Front End Engineering...

GlobeNewswire, Inc.

Patients on Vafseo® (vadadustat) increased to approximately 11,500 at the end of Q3 2026 representing an increase of approximately 140% from the end of Q3 2025 Q3 2026 Vafseo® (vadadustat) net product revenues of $14.8 million, impacted by...

GlobeNewswire, Inc.

ATLANTA, Nov. 09, 2026 (GLOBE NEWSWIRE) -- First Advantage Corporation (“First Advantage”) (NASDAQ: FA), a global software and data company providing comprehensive, end-to-end identity solutions, criminal background screening, credential...

GlobeNewswire, Inc.

Positive GFORCE-1 Phase 1 results showed MRT-8102 reduced key pathogenic drivers of atherosclerotic cardiovascular disease (ASCVD) to levels comparable to healthy volunteers across all three dose levels, with treatment-emergent adverse event rates...

GlobeNewswire, Inc.

Completed merger with Cyclerion Therapeutics and concurrent $380 million private placement Phase 1 healthy volunteer data for KRSA-028 expected mid-2027 and interim proof-of-concept data in Alzheimer’s disease patients anticipated by year-end 2027...

GlobeNewswire, Inc.

CLYM116 Phase 1 data in healthy volunteers showed sustained >90% free APRIL suppression and ~70% Gd-IgA1 reduction at 12 weeks after a single dose, supporting every-12-week dosing Initiated dosing in NAVIGATE-2 Phase 2 trial of CLYM116 in IgAN;...

GlobeNewswire, Inc.

Worldwide revenue of $389.9 million in the third quarter of 2026 GAAP fully diluted earnings per share of $0.33, compared to $0.41 in the third quarter of 2025 Adjusted fully diluted earnings per share of $1.68, compared to $1.27 in the third...